48870 Federal Register / Vol. 62, No. 180 / Wednesday, September 17, 1997 / Notices

(4) medical decision analysis related to the

Bunker Hill site. Scientists with expertise

specific to the health outcomes under

consideration will convene to define

appropriate screening tests to be included in

the medical monitoring program based on the

proposed outcomes and eligible populations.

Also, the workshop will provide ATSDR

guidance in the development of clinical

evaluation protocols that could be included

in a medical monitoring program.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Vivian Rush, M.D., Medical Officer, ATSDR,

Division of Health Education and Promotion,

1600 Clifton Road, NE, M/S E–33, Atlanta,

Georgia 30333, telephone 404/639–5080 or

Gregory Thomas, Senior Regional

Representative, ATSDR Region X, Seattle,

WA 98101, telephone 206/553–2113.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–24637 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Meetings

The National Center for

Environmental Health (NCEH) of the

Centers for Disease Control and

Prevention (CDC) announces the

following Fetal Alcohol Syndrome

(FAS) Prevention meetings:

Name: 1997 Fetal Alcohol Syndrome (FAS)

Surveillance and Prevention Grantees’

Meeting.

Time And Date: 8 a.m.–5:30 p.m.,

September 25, 1997.

Place: Beaver Run Resort and Conference

Center, 620 Village Road, Breckenridge,

Colorado 80424, 970/453–6000.

Status: Open to CDC grantees conducting

FAS epidemiologic surveillance and

prevention projects among various States and

universities. Persons in the general public

wishing to participate may telephone 770/

488–7268, e-mail (GCL1@cdc.gov) or fax

(770/488–7361) their request.

Purpose: The annual meeting of CDC’s FAS

grantees is held in order to exchange

information regarding the funded projects’

activities and progress.

Matters To Be Discussed: Agenda items

include a CDC update related to FAS

epidemiologic surveillance and prevention

activities, and summary reports from each of

the grantees. Agenda items are subject to

change as priorities dictate.

Contact Person For More Information:

Gregg Leeman, Fetal Alcohol Syndrome

Prevention Section, NCEH, CDC, 4770 Buford

Highway, NE, MS:F15, Atlanta, Georgia

30341, telephone 770/488–7268, e-mail

GCL1@cdc.gov, fax 770/488–7361.

Name: Prevention and Management: Fetal

Alcohol Syndrome and Prenatal Substance

Abuse, sponsored by the Colorado Fetal

Alcohol and Substance Abuse Coalition and

CDC’s Division of Birth Defects and

Developmental Disabilities.

Times And Dates: 3 p.m.–7 p.m.,

September 25, 1997; 7:30 a.m.–5 p.m.,

September 26, 1997; 7:30 a.m.–4:30 p.m.,

September 27, 1997.

Place: Beaver Run Resort and Conference

Center, 620 Village Road, Breckenridge,

Colorado 80424, 970/453–6000.

Status: Open. Persons wishing to

participate in the conference may register by

contacting Elizabeth Franz, telephone 303/

756–8380; e-mail fasconf@aol.com; or fax

303/759–8861. The conference registration

fee is $175.00.

Purpose: Conference objectives are to

present: Effective models for identification of

and intervention with high-risk women;

current research on screening and diagnostic

methods and interventions for the child

prenatally exposed to alcohol; current public

health and epidemiological data; current

research about the effects of alcohol and

other drugs on fetal development; to discuss

policy, legal and criminal justice issues

related to FAS; and to explore communitybased prevention programs.

Matters To Be Discussed: The conference is

built around six areas of emphasis:

Intervention with high-risk women; Working

with the FAS affected child; Public health

and epidemiology; Clinical and research

issues; Policy and legal issues; Community

issues and prevention programs.

Contact Person For More Information:

Elizabeth Franz, Colorado Fetal Alcohol and

Substance Abuse Coalition Conference

Office, telephone 303/756–8380, fax 303/

759–8861, e-mail fasconf@aol.com.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–24635 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Council for the Elimination of

Tuberculosis: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following meeting.

Name: Advisory Council for the

Elimination of Tuberculosis (ACET).

Times and Dates: 8:30 a.m.–5 p.m.,

October 16, 1997; 8:30 a.m.–12 p.m., October

17, 1997.

Place: Corporate Square Office Park,

Corporate Square Boulevard, Building 11,

Room 1413, Atlanta, Georgia 30329.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 100 people.

Purpose: The Council advises and makes

recommendations to the Secretary of Health

and Human Services, the Assistant Secretary

for Health, and the Director, CDC, regarding

the elimination of tuberculosis. Specifically,

the Council makes recommendations

regarding policies, strategies, objectives, and

priorities; addresses the development and

application of new technologies; and reviews

the extent to which progress has been made

toward eliminating tuberculosis.

Matters to be Discussed: Agenda items

include follow-up discussion on issues

related to isoniazid prevention therapy;

discussions on scientific basis of TB vaccine;

TB vaccine development and

implementation; economic issues relating to

TB vaccines; and developing long term goals

and/or issues of ACET. Agenda items are

subject to change as priorities dictate.

Contact Person For More Information: Janet

Cleveland, National Center for HIV, STD, and

TB Prevention, 1600 Clifton Road, NE, M/S

E–07, Atlanta, Georgia 30333, telephone 404/

639–8008.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–24636 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0022]

Agency Information Collection

Activities; Submission for OMB

Review; Comment Request

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that the proposed collection of

information listed below has been

submitted to the Office of Management

and Budget (OMB) for review and

clearance under the Paperwork

Reduction Act of 1995 (the PRA).

DATES: Submit written comments on the

collection of information by October 17,

1997.

ADDRESSES: Submit written comments

on the collection of information to the

Office of Information and Regulatory

Affairs, OMB, New Executive Office

Bldg., 725 17th St. NW., rm. 10235,

Washington, DC 20503, Attention: Desk

Officer for FDA.

FOR FURTHER INFORMATION CONTACT:

Judith V. Bigelow, Office of Information
Federal Register / Vol. 62, No. 180 / Wednesday, September 17, 1997 / Notices 48871

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–1479.

SUPPLEMENTARY INFORMATION: In

compliance with section 3507 of the

PRA (44 U.S.C. 3507), FDA has

submitted the following proposed

collection of information to OMB for

review and clearance:

Notice of Availability of Sample

Electronic Product—21 CFR Parts 1020,

1030, 1040, and 1050 and FDA Form

2767 (OMB Control No. 0910–0048—

Reinstatement)

Under sections 532 through 542 of the

Federal Food, Drug, and Cosmetic Act

(the act) (21 U.S.C. 360ii through 360ss),

FDA regulates electronic products that

emit radiation. Section 532 of the act

directs the Secretary of the Department

of Health and Human Services (the

Secretary) to establish and carry out an

electronic product radiation control

program designed to protect the public

health and safety from electronic

radiation, and authorizes the Secretary

to procure (by negotiation or otherwise)

electronic products for research and

testing purposes and to sell or otherwise

dispose of such products.

FDA’s Center for Devices and

Radiological Health (CDRH) conducts

laboratory compliance testing of

products covered by regulations for

product standards in parts 1020, 1030,

1040, and 1050 (21 CFR parts 1020,

1030, 1040, and 1050). The ‘‘Notice of

Availability of Sample Electronic

Product’’ (Form FDA 2767) is used to

inform CDRH of the location of sample

products that are being requested for

testing to confirm that the products

comply with performance standards.

Form FDA 2767 is a summary form

which reports information as required

by parts 1020, 1030, 1040, and 1050.

FDA also uses this information to

locate and select sample products to

ensure conformance with regulations. In

the event this information were not

collected by CDRH, each manufacturer

would have to respond in letter format

with all the data now being recorded on

Form FDA 2767, which would require

more time and expense. Testing an

appropriate percentage of these

products to protect the public would

also be hindered by the slower process.

The respondents to this collection of

information are manufacturers of

electronic products.

FDA estimates the burden of this

collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN

21 CFR Part and Form Number No. of

Respondents

Annual

Frequency per

Response

Total Annual

Responses

Hours per

Response Total Hours

1020, 1030, 1040, 1050, and Form FDA 2767 145 11.03 1,600 0.09 144

Totals 144

There are no capital costs or operating and maintenance costs associated with this collection of information.

FDA’s estimates are based on actual

data collected from industry over the

past 3 years, where there has been an

average of 1,600 annual responses to

FDA from 145 respondents each year.

Dated: September 9, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–24581 Filed 9–16–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Care Financing Administration

[HCFA–R–52]

Agency Information Collection

Activities: Proposed Collection;

Comment Request

AGENCY: Health Care Financing

Administration, HHS.

In compliance with the requirement

of section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Health Care Financing Administration

(HCFA), Department of Health and

Human Services, is publishing the

following summary of proposed

collections for public comment.

Interested persons are invited to send

comments regarding this burden

estimate or any other aspect of this

collection of information, including any

of the following subjects: (1) The

necessity and utility of the proposed

information collection for the proper

performance of the agency’s functions;

(2) the accuracy of the estimate burden;

(3) ways to enhance the quality, utility,

and clarity of the information to be

collected; and (4) the use of automated

collection techniques or other forms of

information technology to minimize the

information collection burden.

Type of Information Collection

Request: Revision of a currently

approved collection; Title of

Information Collection: Conditions for

Coverage of Supplier of End Stage Renal

Disease (ESRD) Services and Supporting

Regulations Contained in 42 CFR

405.2100–2171; Document No.: HCFA–

R–52 (OMB#0938–0386); Use: These

conditions of coverage are needed to

ensure proper distribution and effective

utilization of ESRD treatment sources.

In addition, the conditions maintain and

improve the efficient delivery of care by

physicians and dialysis facilities;

Frequency: Annually; Affected Public:

Business or other for-profit, and Federal

Government; Number of Respondents:

2,976; Total Annual Responses: 2,976,

Total Annual Hours: 100,937.

To obtain copies of the supporting

statement and any related forms for the

proposed paperwork collections

referenced above, E-mail your request,

including your address, phone number,

OMB number, and HCFA document

identifier to Paperwork@hcfa.gov, or

call the Reports Clearance Office on

(410) 786–1326. Written comment and

recommendations for the proposed

information collections must be mailed

within 60 days of this notice directly to

the HCFA Paperwork Clearance Officer

designated at the following address:

HCFA, Office of Information Services,

Information Technology Investment

Management Group, Division of HCFA

Enterprise Standards, Attention: Louis

Blank, Room C2–26–17, 7500 Security

Boulevard, Baltimore, Maryland, 21244–

1850.

Dated: September 10, 1997.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office

of Information Services, Information

Technology Investment Management Group,

Division of HCFA Enterprise Standards.

[FR Doc. 97–24652 Filed 9–16–97; 8:45 am]

BILLING CODE 4120–03–M